Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Dyslipidemia Market is Anticipated to Accelerate in the Coming 10 Years Due to the Development of New Classes of Drugs, Such as CETP Inhibitors and Gene-based Therapies | DelveInsight

      DelveInsight Business Research, LLP Logo

      News provided by

      DelveInsight Business Research, LLP

      Sep 11, 2025, 17:31 ET

      Share this article

      Share this article


      The dyslipidemia market is expected to witness significant growth, driven by an aging population, increasing awareness of cardiovascular health, and the introduction of novel therapies such as AZD0780, Obicetrapib, Plozasiran (ARO-APOC3), Zodasiran (ARO-ANG3), and others. The anticipated approval of emerging drugs is likely to enhance treatment options and improve patient outcomes.

      LAS VEGAS, Sept. 11, 2025 /PRNewswire/ -- DelveInsight's Dyslipidemia Market Insights report includes a comprehensive understanding of current treatment practices, dyslipidemia emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan).

      Dyslipidemia Market Summary

      • According to DelveInsight's analysis, the market size for dyslipidemia in the leading markets (the US, EU4, UK, and Japan) is expected to grow significantly by 2034.
      • The United States accounted for the highest dyslipidemia treatment market size in 7MM in 2024, in comparison to the other major markets, i.e., EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
      • Estimates suggest that in Japan, 47.7% of men and 27.1% of women had dyslipidemia. In men, dyslipidemia increased with age, peaking at 51.2% for those aged 50–59, while it rose linearly in women, reaching 47.3% for those aged 60–69.
      • Leading dyslipidemia companies developing emerging therapies, such as AstraZeneca, NewAmsterdam Pharma, Arrowhead Pharmaceuticals, and others, are developing new therapy for dyslipidemia that can be available in the Dyslipidemia market in the coming years. 
      • The promising dyslipidemia therapies in clinical trials include AZD0780, Obicetrapib, Plozasiran (ARO-APOC3), Zodasiran (ARO-ANG3), and others.

      Discover the dyslipidemia new treatment @ New Treatments for Dyslipidemia

      Key Factors Driving the Growth of the Dyslipidemia Market 

      Rising Prevalence of Cardiovascular Diseases

      The increasing incidence of heart disease and stroke worldwide is a primary driver for the demand for effective lipid-lowering treatments. DelveInsight analysts project that the prevalence of dyslipidemia is expected to grow during the forecast period (2025-2034), attributed to a rise in cardiovascular diseases and an aging population. This trend is influenced by the increased consumption of processed foods, sugary drinks, and foods high in saturated and trans fats, all of which negatively impact lipid profiles.

      Advancements in Diagnostic Technologies

      Technological innovations in lipid profiling, genetic testing, and telemedicine platforms have enhanced early detection and monitoring of dyslipidemia. These advancements facilitate timely interventions and personalized treatment plans, increasing the adoption of lipid-lowering therapies.

      Emergence of New Dyslipidemia Drug Classes

      Development of new classes of drugs, such as CETP inhibitors (NewAmsterdam Pharma's Obicetrapib) and gene-based therapies, holds promise for better management of dyslipidemia.

      Launch of Emerging Dyslipidemia Drugs

      The dyslipidemia market is anticipated to be driven in the coming years due to the rise in novel drugs and therapies such as AZD0780 (AstraZeneca), Obicetrapib (NewAmsterdam Pharma), Plozasiran (ARO-APOC3) (Arrowhead Pharmaceuticals), Zodasiran (ARO-ANG3) (Arrowhead Pharmaceuticals), and others.

      Dyslipidemia Market Analysis

      The approach to managing dyslipidemia varies with its severity. Statins are generally the first-line therapy for severe cases, while other options include PCSK9 inhibitors, fibrates, and bile acid sequestrants. In addition, lifestyle interventions, such as regular physical activity, healthy eating, and maintaining a healthy weight—play a key role in effective control. Some of the approved dyslipidemia drugs are PRALUENT, REPATHA, LEQVIO, LOMITAPIDE, and NEXLETOL.

      PRALUENT (alirocumab), a PCSK9 inhibitor monoclonal antibody, is prescribed alongside diet and maximally tolerated statin therapy for adults and children (aged 8 years and older) with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) who need further reduction in LDL cholesterol (LDL-C).

      REPATHA (evolocumab), a fully human IgG2 monoclonal antibody against PCSK9, has been available since 2015. It is indicated to lower LDL-C in adults and children (aged 10 years and above) with primary hyperlipidemia, including both HeFH and HoFH, and is also used to reduce the risk of major cardiovascular events in patients with established cardiovascular disease.

      LEQVIO (inclisiran, KJX839) is the first small interfering RNA (siRNA) therapy that lowers LDL-C through an RNA interference (RNAi) mechanism. It represents a novel treatment option for patients with ASCVD, with approvals granted by the EMA in December 2020, and subsequently in the United States and Japan.

      To know more about dyslipidemia treatment options, visit @ Approved Dyslipidemia Drugs

      Dyslipidemia Competitive Landscape

      Some of the dyslipidemia drugs in clinical trials include Obicetrapib (NewAmsterdam Pharma), Zodasiran (Arrowhead Pharmaceuticals), AZD0780 (AstraZeneca), and others. 

      AZD0780 is an orally administered small-molecule inhibitor of PCSK9, a key regulator of cholesterol metabolism. Elevated PCSK9 activity is linked to increased LDL cholesterol levels, and its inhibition is expected to lower LDL-C and reduce cardiovascular risk. The compound is currently being evaluated in a Phase II/III trial for dyslipidemia. In a Phase I study, AZD0780 combined with statins achieved marked reductions in LDL-C, with results presented at the European Atherosclerosis Society (EAS) meeting in France.

      Obicetrapib, developed by NewAmsterdam Pharma, is a highly selective CETP inhibitor aimed at lowering LDL-C by reducing hepatic cholesterol, thereby increasing LDL receptor expression and promoting LDL clearance. It is under investigation as an add-on to maximally tolerated lipid-lowering regimens in patients with ASCVD, HeFH, or equivalent cardiovascular risk. Three pivotal Phase III studies—BROADWAY, BROOKLYN, and PREVAIL—have been conducted, with BROADWAY and BROOKLYN completed. In contrast, fixed-dose obicetrapib/ezetimibe combinations are being studied in TANDEM (completed) and REMBRANDT. At the May 2025 EAS Congress, NewAmsterdam reported late-breaking data from BROADWAY and TANDEM, published in NEJM and The Lancet, respectively. Obicetrapib reduced LDL-C by 35% as monotherapy and up to 50% when combined with ezetimibe. Earlier Phase II data demonstrated LDL-C reductions of ~70% with moderate-dose statins. In BROADWAY, treatment was associated with a 21% reduction in major adverse cardiovascular events (HR=0.79, CI 0.54–1.15).

      Plozasiran (formerly ARO-APOC3) is an RNAi-based therapy that lowers Apolipoprotein-CIII (ApoC3) production in hepatocytes. ApoC3 inhibits the metabolism and clearance of lipids and lipoproteins, including triglycerides. In January 2025, Arrowhead Pharmaceuticals announced that the US FDA accepted the New Drug Application for plozasiran in familial chylomicronemia syndrome, supported by positive Phase III PALISADE data, with a PDUFA target date of November 18, 2025. Beyond FCS, the therapy is also in development for severe hypertriglyceridemia and dyslipidemia.

      The anticipated launch of these emerging therapies is poised to transform the dyslipidemia market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the dyslipidemia market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

      Discover more about therapy for dyslipidemia @ Dyslipidemia Clinical Trials 

      Recent Developments in the Dyslipidemia Market

      • In March 2025, positive results from the Phase IIb PURSUIT trial were presented at the American College of Cardiology's Annual Scientific Session and Expo (ACC) and simultaneously published in the Journal of the American College of Cardiology (JACC). The findings showed that AstraZeneca's oral PCSK9 inhibitor, AZD0780, led to a statistically significant reduction in low-density lipoprotein cholesterol (LDL-C) when added to standard-of-care statin therapy. 

      Dyslipidemia Overview

      Dyslipidemia refers to an imbalance in cholesterol and lipoprotein levels, including High-Density Lipoprotein (HDL) and Low-Density Lipoprotein (LDL). While these molecules are vital for normal cell function, elevated concentrations can significantly raise the risk of heart attack and other serious health problems.

      Dyslipidemia Epidemiology Segmentation

      The dyslipidemia epidemiology section provides insights into the historical and current dyslipidemia patient pool and forecasted trends for the leading markets (the US, EU4, UK, and Japan). It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.

      The dyslipidemia market report proffers epidemiological analysis for the study period 2020–2034 in the leading markets (the US, EU4, UK, and Japan), segmented into:

      • Total Prevalent Cases of Dyslipidemia
      • Total Diagnosed Prevalent Cases of Dyslipidemia
      • Age-specific Diagnosed Prevalent Cases of Dyslipidemia
      • Gender-specific Diagnosed Prevalent Cases of Dyslipidemia
      • Treated Cases of Dyslipidemia

      Dyslipidemia Market Report Metrics

      Details

      Study Period

      2020–2034

      Dyslipidemia Market Report Coverage

      7MM [The United States, the EU4 (Germany, France, Italy, and Spain) the United Kingdom, and Japan].

      Dyslipidemia Epidemiology Segmentation

      Total Prevalent Cases of Dyslipidemia, Total Diagnosed Prevalent Cases of Dyslipidemia, Age-specific Diagnosed Prevalent Cases of Dyslipidemia, Gender-specific Diagnosed Prevalent Cases of Dyslipidemia, and Treated Cases of Dyslipidemia

      Key Dyslipidemia Companies

      AstraZeneca, NewAmsterdam Pharma, Arrowhead Pharmaceuticals, Amgen, Sanofi, Novartis, Amryt Pharma, Esperion Therapeutics, and others

      Key Dyslipidemia Therapies

      AZD0780, Obicetrapib, Plozasiran (ARO-APOC3), Zodasiran (ARO-ANG3), REPATHA, PRALUENT, LEQVIO, LOMITAPIDE, NEXLETOL, and others

      Scope of the Dyslipidemia Market Report

      • Therapeutic Assessment: Dyslipidemia current marketed and emerging therapies
      • Dyslipidemia Market Dynamics: Key Market Forecast Assumptions of Emerging Dyslipidemia Drugs and Market Outlook
      • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
      • Unmet Needs, KOL's views, Analyst's views, Dyslipidemia Market Access and Reimbursement

      Download the report to understand which factors are driving dyslipidemia therapeutics market trends @ Dyslipidemia Market Trends

      Table of Contents

      1

      Dyslipidemia Market Key Insights

      2

      Dyslipidemia Market Report Introduction

      3

      Dyslipidemia Market Overview

      3.1

      Market Share (%) Distribution of Dyslipidemia by Therapies in 2024

      3.2

      Market Share (%) Distribution of Dyslipidemia by Therapies in 2034

      4

      Methodology of Dyslipidemia Epidemiology and Market

      5

      Executive Summary

      6

      Key Events

      7

      Dyslipidemia Disease Background and Overview

      7.1

      Introduction

      7.2

      Dyslipidemia Signs and Symptoms

      7.3

      Dyslipidemia Diagnosis

      7.4

      Dyslipidemia Treatment and Management

      8

      Dyslipidemia Epidemiology and Patient Population

      8.1

      Key Findings

      8.2

      Epidemiology Assumptions: The 7MM

      8.3

      Total Prevalent Cases of Dyslipidemia in the 7MM

      8.4

      Total Diagnosed Prevalent Cases of Dyslipidemia in the 7MM

      8.5

      The US

      8.6

      EU4 and the UK

      8.7

      Japan

      9

      Dyslipidemia Patient Journey

      10

      Marketed Dyslipidemia Therapies

      10.1

      Key Cross Competition

      10.2

      REPATHA (Evolocumab): Amgen

      10.2.1

      Product Description

      10.2.2

      Regulatory Milestone

      10.2.3

      Other Developmental Activities

      10.2.4

      Clinical Trials Information

      10.2.5

      Safety and Efficacy

      10.3

      PRALUENT (alirocumab): Sanofi

      10.4

      LEQVIO (inclisiran, KJX839): Novartis

      10.5

      LOMITAPIDE (aegerion): Amryt Pharma

      10.6

      NEXLETOL (bempedoic acid): Esperion Therapeutics

      List to be continued in the final report.

      11

      Emerging Dyslipidemia Therapies

      11.1

      Key Cross Competition

      11.2

      AZD0780: AstraZeneca

      11.2.1

      Drug Description

      11.2.2

      Other Developmental Activities

      11.2.3

      Clinical Trials Information

      11.2.4

      Safety and Efficacy

      11.2.5

      Analysts' View

      11.3

      Obicetrapib: NewAmsterdam Pharma

      11.4

      Plozasiran (ARO-APOC3): Arrowhead Pharmaceuticals

      11.5

      Zodasiran (ARO-ANG3): Arrowhead Pharmaceuticals

      List to be continued in the final report.

      12

      Dyslipidemia Market Analysis

      12.1

      Key Findings

      12.2

      Key Dyslipidemia Market Forecast Assumptions

      12.3

      Dyslipidemia Market Outlook

      12.4

      Attribute Analysis

      12.5

      Total Market Size of Dyslipidemia in the 7MM

      12.6

      Market Size of Dyslipidemia by Therapies in the 7MM

      12.7

      The US Dyslipidemia Market Size

      12.7.1

      Total Market Size of Dyslipidemia

      12.7.2

      Market size of Dyslipidemia by Therapies

      12.8

      EU4 and the UK Dyslipidemia Market Size

      12.9

      Japan Dyslipidemia Market Size

      13

      Key Opinion Leaders' Views on Dyslipidemia 

      14

      Dyslipidemia Market SWOT Analysis

      15

      Dyslipidemia Market Unmet needs

      16

      Dyslipidemia Market Access and Reimbursement

      16.1

      The US

      16.2

      In EU4 and the UK

      16.3

      Japan

      17

      Bibliography

      18

      Acronyms and Abbreviations

      19

      Dyslipidemia Market Report Methodology

      Related Reports

      Dyslipidemia Clinical Trial Analysis 

      Dyslipidemia Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key dyslipidemia companies, including AstraZeneca, NewAmsterdam Pharma, Arrowhead Pharmaceuticals, Amgen, Sanofi, Novartis, Amryt Pharma, Esperion Therapeutics, among others.

      PCSK9 Inhibitors Market

      PCSK9 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key PCSK9 inhibitors companies, including LIB Therapeutics, Merck, Verve Therapeutics, CiVi Biopharma, among others.

      Familial Hypercholesterolemia Market

      Familial Hypercholesterolemia Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key familial hypercholesterolemia companies, including Sanofi, Regeneron Pharmaceuticals, Amgen, Esperion Therapeutics, Aegerion Pharmaceutical, Esperion Therapeutics, Regeneron Pharmaceuticals, Novartis, LIB Therapeutics, NeuroBo Pharmaceuticals, Arrowhead Pharmaceuticals, among others.

      Hypercholesterolemia Market

      Hypercholesterolemia Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key hypercholesterolemia companies, including Novartis Pharmaceuticals, Merck Sharp & Dohme LLC, Esperion Therapeutics, Inc., Arrowhead Pharmaceuticals, LIB Therapeutics LLC, Medpace, Inc., AstraZeneca, NewAmsterdam Pharma, among others.

      About DelveInsight

      DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

      Contact Us
      Shruti Thakur
      [email protected]
      +14699457679
      www.delveinsight.com

      Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

      SOURCE DelveInsight Business Research, LLP

      Modal title

      Also from this source

      Epilepsy Market Set to Grow During the Forecast Period (2026-2036) as Novel Antiseizure Therapies Gain Momentum | DelveInsight

      Epilepsy Market Set to Grow During the Forecast Period (2026-2036) as Novel Antiseizure Therapies Gain Momentum | DelveInsight

      Recently published Epilepsy Market Insights report includes a comprehensive understanding of current treatment practices, epilepsy emerging drugs,...

      JAK Inhibitors Market to Register Notable Growth During the Forecast Period (2026-2036) Through Expanding Clinical and Commercial Landscape | DelveInsight

      JAK Inhibitors Market to Register Notable Growth During the Forecast Period (2026-2036) Through Expanding Clinical and Commercial Landscape | DelveInsight

      DelveInsight's JAK Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Pharmaceuticals

      Pharmaceuticals

      Biotechnology

      Biotechnology

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.